• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janet Woodcock in the Running for FDA Chief in Biden Administration

Janet Woodcock in the Running for FDA Chief in Biden Administration

January 18, 2021

FDA veteran Janet Woodcock has reportedly been short-listed by the incoming Biden administration to serve as the agency’s next commissioner and will also likely serve as acting chief until the position is filled.

Woodcock is expected to assume the role of acting FDA commissioner on Jan. 20 after President-elect Biden is inaugurated and current chief Stephen Hahn steps down from the agency.

Woodcock, who took leave from her position as director of the agency’s Center for Drug Evaluation and Research (CDER) to serve as the COVID-19 therapeutics adviser to the Trump administration’s Operation Warp Speed (OWS) initiative, is now reportedly being considered to lead the agency in a permanent capacity.

The long-time CDER director just last week returned to the FDA as principal medical adviser to Hahn and is now performing her OWS duties in addition to her new advisory role at the agency.

But Woodcock is not the only candidate on the Biden team’s short list for FDA commissioner. Joshua Sharfstein is also reportedly in the running for the post. A physician with an extensive public health background, Sharfstein previously served as FDA principal deputy commissioner from 2009 to 2011 and led former President Obama’s FDA transition team. He is currently vice dean for public health practice and community engagement at Johns Hopkins Bloomberg School of Public Health.

The Biden transition team did not respond to requests for confirmation of the shortlisted candidates and the FDA declined to comment.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing